| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding | |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | Entrez:933 MIM:107266 HGNC:HGNC:1643 Ensembl:ENSG00000012124 AllianceGenome:HGNC:1643 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | CD22 molecule | |||||
| GTO ID | GTC2471 |
| Trial ID | NCT04571138 |
| Disease | Lymphoma | Leukemia |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | SCRI-CAR22v2 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma |
| Year | 2020 |
| Country | United States |
| Company sponsor | Seattle Children's Hospital |
| Other ID(s) | PLAT-07 |
| Cohort 1 | |||||||||
|
|||||||||